Skip to main content
Top
Published in: Diabetes Therapy 1/2018

Open Access 01-02-2018 | Original Research

Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes

Authors: Tejasav Sehrawat, Anuraag Jindal, Paaras Kohli, Amit Thour, Jasbinder Kaur, Atul Sachdev, Yashdeep Gupta

Published in: Diabetes Therapy | Issue 1/2018

Login to get access

Abstract

Introduction

To study the utility of glycated hemoglobin (HbA1c) in the diagnosis of diabetes in patients with cirrhosis as compared to the gold standard oral glucose tolerance test (OGTT) and to see the effect of anemia and severity of cirrhosis on its performance.

Methods

Individuals (n = 100) with an established diagnosis of liver cirrhosis were recruited. The OGTT was performed as described by the World Health Organization (WHO). The severity of cirrhosis was calculated using the Child–Turcotte–Pugh (CTP) score. The severity of anemia was defined according to WHO criteria. The utility of HbA1c was compared against the OGTT results. Test sensitivity and specificity were used to describe the diagnostic accuracy of HbA1c.

Results

A total of 100 subjects aged 46.9 ± 9.1 years (mean ± standard deviation) participated in the study, of whom 65% were recruited from out patient department of our hospital. The overall sensitivity and specificity of a HbA1c level of ≥ 6.5% for the diagnosis of diabetes in patients with cirrhosis was 77.1% (95% CI 59.9, 89.6) and 90.8% (95% CI 81.0, 96.5), respectively. The positive and negative predictive values were 81.8% (95% CI 67.3, 90.8) and 88.1% (95% CI 80.0, 93.2), respectively. The area under the curve was 0.85 (95% CI 0.75–0.94). The sensitivity of HbA1c for diagnosing diabetes in outpatients was 87.0% (95% CI 66.4, 97.2) and was better than that for diagnosing diabetes in hospitalized patients (58.3%; 95% CI 27.7, 84.8). The sensitivity of HbA1c for diagnosing diabetes was poor in patients with moderate to severe anemia. The difference in sensitivity and specificity was not statistically different for CTP classes A, B and C. The prevalence of diabetes as defined by American Diabetes Association OGTT criteria was 35% (95% CI 25.7–45.2%).

Conclusions

Taking OGTT as the gold standard, the sensitivity of HbA1c for diagnosing diabetes is good when used in outpatients with cirrhosis. However, the sensitivity of HbA1c decreases when it is used for hospitalized patients, suggesting that it is not a good test for diagnosis of diabetes in such cases. It also performs poorly if the patient has moderate to severe anemia.
Literature
3.
go back to reference Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed
4.
go back to reference Elkrief L, Rautou PE, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936–48.CrossRefPubMed Elkrief L, Rautou PE, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936–48.CrossRefPubMed
5.
go back to reference Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–94.CrossRefPubMed Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–94.CrossRefPubMed
6.
go back to reference American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13–27.CrossRef American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13–27.CrossRef
8.
go back to reference GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef
10.
go back to reference Orsi E, Grancini V, Menini S, et al. Hepatogenous diabetes: is it time to separate it from type 2 diabetes? Liver Int. 2017;37:950–62.CrossRefPubMed Orsi E, Grancini V, Menini S, et al. Hepatogenous diabetes: is it time to separate it from type 2 diabetes? Liver Int. 2017;37:950–62.CrossRefPubMed
12.
go back to reference Cacciatore L, Cozzolino G, Giardina MG, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res. 1988;7:185–8.PubMed Cacciatore L, Cozzolino G, Giardina MG, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res. 1988;7:185–8.PubMed
13.
go back to reference Nomura Y, Nanjo K, Miyano M, et al. Hemoglobin A1 in cirrhosis of the liver. Diabetes Res. 1989;11:177–80.PubMed Nomura Y, Nanjo K, Miyano M, et al. Hemoglobin A1 in cirrhosis of the liver. Diabetes Res. 1989;11:177–80.PubMed
14.
go back to reference Lahousen T, Hegenbarth K, Ille R, et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol. 2004;10:2284–6.CrossRefPubMedPubMedCentral Lahousen T, Hegenbarth K, Ille R, et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol. 2004;10:2284–6.CrossRefPubMedPubMedCentral
15.
go back to reference Trenti T, Cristani A, Cioni G, et al. Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis. Int J Clin Lab Res. 1990;20:261–7. Trenti T, Cristani A, Cioni G, et al. Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis. Int J Clin Lab Res. 1990;20:261–7.
16.
go back to reference Shetty A, Wilson S, Kuo P, et al. Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation. 2000;69:2451–4.CrossRefPubMed Shetty A, Wilson S, Kuo P, et al. Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation. 2000;69:2451–4.CrossRefPubMed
17.
go back to reference Lunati ME, Grancini V, Agnelli F, et al. Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. Dig Liver Dis. 2013;45:833–9.CrossRefPubMed Lunati ME, Grancini V, Agnelli F, et al. Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. Dig Liver Dis. 2013;45:833–9.CrossRefPubMed
18.
go back to reference Grancini V, Trombetta M, Lunati ME, et al. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease. J Hepatol. 2015;63:1484–90.CrossRefPubMed Grancini V, Trombetta M, Lunati ME, et al. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease. J Hepatol. 2015;63:1484–90.CrossRefPubMed
19.
go back to reference Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95:e2877.CrossRef Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95:e2877.CrossRef
21.
go back to reference World Health Organization. Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus 1999. http://apps.who.int/iris/handle/10665/66040. Accessed 16 Dec World Health Organization. Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus 1999. http://​apps.​who.​int/​iris/​handle/​10665/​66040. Accessed 16 Dec
22.
go back to reference Anjana RM, Pradeepa R, Deepa M, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54:3022–7.CrossRefPubMed Anjana RM, Pradeepa R, Deepa M, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54:3022–7.CrossRefPubMed
23.
24.
go back to reference English E, Idris I, Smith G, et al. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58:1409–21.CrossRefPubMed English E, Idris I, Smith G, et al. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58:1409–21.CrossRefPubMed
25.
go back to reference Hardikar PS, Joshi SM, Bhat DS, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young Indians partly explained by haematological factors and iron deficiency anemia. Diabetes Care. 2012;35:797–802.CrossRefPubMedPubMedCentral Hardikar PS, Joshi SM, Bhat DS, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young Indians partly explained by haematological factors and iron deficiency anemia. Diabetes Care. 2012;35:797–802.CrossRefPubMedPubMedCentral
Metadata
Title
Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes
Authors
Tejasav Sehrawat
Anuraag Jindal
Paaras Kohli
Amit Thour
Jasbinder Kaur
Atul Sachdev
Yashdeep Gupta
Publication date
01-02-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 1/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-017-0362-4

Other articles of this Issue 1/2018

Diabetes Therapy 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.